Pierrepont Therapeutics

Pierrepont Therapeutics, Inc. is dedicated to developing targeted treatments for primary mitochondrial and other rare genetic diseases. Pierrepont's lead product candidate, PTI-501 (formerly ENTR-501) is a proprietary intracellular enzyme replacement therapy for the treatment of MNGIE that is exclusively licensed from Entrada Therapeutics, Inc.(Nasdaq: TRDA). The founders of Pierrepont have unique expertise and success in mitochondrial disease drug development, and have strong relationships with KOLS, families, and patient advocacy groups in the mitochondrial disease community. For more information, please contact info@PierrepontTx.com.